( NYSE:LLY )

News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 19, 2016, 05:00 ET Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine...


Apr 15, 2016, 16:17 ET FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...


Apr 13, 2016, 08:00 ET Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology

 Results from LUX-Lung 7, a global head-to-head Phase IIb trial comparing treatment with Gilotrif® (afatinib) to Iressa® (gefitinib)...


Apr 08, 2016, 07:00 ET Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy

 Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients...


Apr 02, 2016, 11:30 ET Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the results of a new interim analysis of data from the ongoing phase III RE-VERSE...


Mar 31, 2016, 09:00 ET The 4WARD Coalition™ Launches AFib4WARD.com to Encourage Shared Decision Making Between AFib Patients and Healthcare Providers

 Today the 4WARD Coalition launched AFib4WARD.com, an online tool designed to help non-valvular atrial fibrillation (AFib) patients and their...


Mar 29, 2016, 08:00 ET FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD Health-Related Quality of Life

 Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved a sNDA for STIOLTO...


Mar 23, 2016, 08:00 ET Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the enrollment of the first patient in RE-COVERY DVT/PE™, a global...


Mar 23, 2016, 07:00 ET Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma

 Propeller Health, the leading digital health solution for respiratory medicine, and Boehringer Ingelheim Pharmaceuticals Inc., a global...


Mar 15, 2016, 08:00 ET Boehringer Ingelheim Cares Foundation and AmeriCares Launch Health Coach Program for the Uninsured

 Boehringer Ingelheim Cares Foundation and AmeriCares today announced a new Health Coach Program at the Boehringer Ingelheim AmeriCares...


Mar 08, 2016, 08:00 ET Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals

Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate...


Mar 07, 2016, 12:45 ET New Analyses: Adding SPIRIVA® RESPIMAT® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA®...


Feb 29, 2016, 15:25 ET Boehringer Ingelheim lança medicamento inédito para doença rara e revoluciona panorama de tratamento da Fibrose Pulmonar Idiopática

 A Boehringer Ingelheim, uma das 20 principais farmacêuticas do mundo, anuncia o lançamento de OFEV® (nintedanibe) no Brasil,...


Feb 25, 2016, 08:00 ET New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Pooled analysis from the TOMORROW and INPULSIS® trials, recently published in Respiratory Medicine, confirmed that OFEV reduces the risk of...


Feb 18, 2016, 08:00 ET Country Music Artist Joe Nichols Raises Awareness of Rare Lung Disease That Claimed His Father's Life and Leaves Those Affected "Breathless"

 Award-winning country music artist, Joe Nichols is teaming up with Boehringer Ingelheim Pharmaceuticals, Inc. to raise awareness of the...


Feb 09, 2016, 08:00 ET Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the publication of data that show STIOLTO RESPIMAT improved lung function across a range...


Feb 03, 2016, 08:00 ET SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma...


Jan 25, 2016, 08:30 ET U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on...


Dec 21, 2015, 08:00 ET Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...


Dec 14, 2015, 08:00 ET First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a new 12-week study (ClinicalTrials.gov Identifier: NCT02579603)...


Dec 08, 2015, 08:00 ET New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched

 Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in...


Dec 02, 2015, 08:00 ET Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...


Nov 23, 2015, 10:24 ET FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved...


Nov 18, 2015, 11:30 ET Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index

 Boehringer Ingelheim announced today that it has been recognized on the 2016 Corporate Equality Index (CEI). This is the eighth time that the...